Enap, tablets 5 mg 20 pcs
€1.64 €1.49
Enap is an antihypertensive drug whose mechanism of action is associated with inhibition of angiotensin-converting enzyme activity, resulting in reduction of angiotensin-II formation.
Enalapril is a “prodrug”: as a result of its hydrolysis it produces enalaprilate which inhibits ACE. Its mechanism of action is related to the reduction of angiotensin I to angiotensin II, the reduction of which leads to a direct reduction of aldosterone secretion. This decreases total peripheral vascular resistance, systolic and diastolic blood pressure (BP), post- and preload on myocardium.
Dilates arteries to a greater extent than veins, and there is no reflex increase in heart rate.
The hypotensive effect is more pronounced at high plasma renin levels than at normal or reduced levels. Reduction of blood pressure (BP) within therapeutic limits has no effect on the cerebral blood flow, the blood flow in the brain vessels is maintained at a sufficient level even against the background of reduced blood pressure. It enhances coronary and renal blood flow.
Long-term use reduces hypertrophy of the left ventricular myocardium and myocytes of the resistive arterial walls, prevents the progression of heart failure and slows the development of left ventricular dilatation. Improves blood supply to ischemic myocardium. Reduces platelet aggregation.
It has some diuretic effect.
The time of onset of hypotensive effect when taken orally is 1 hour, reaches a maximum after 4-6 hours and lasts up to 24 hours. In some patients, therapy for several weeks is necessary to achieve optimal blood pressure levels. In cardiac insufficiency noticeable clinical effect is observed with long-term use – 6 months or more.
Indications
Active ingredient
Composition
1 tablet contains:
Enalapril maleate 10 mg.
Auxiliary substances:
Lactose monohydrate,
Hydroxypropylcellulose,
corn starch,
sodium bicarbonate,
talk,
Magnesium stearate.
How to take, the dosage
The drug Enap is administered orally, regardless of the time of meals. The initial dose of Enap is 10-20 mg per day (once daily).
Thereafter, the dose is adjusted individually for each patient – usually 20 mg once a day.
The maximum daily dose should not exceed 40 mg.
In cases of heart failure, the dose is prescribed starting at 2.5 mg, then the dose is gradually increased to 10 to 20 mg (in one to two doses).
Interaction
The patient should refrain from drinking alcoholic beverages because ethanol increases the reduction of blood pressure (BP) with enalapril.
The concomitant use of enalapril and diuretics or other hypotensive agents increases the effectiveness of these drugs.
The interaction with drugs used to treat heart failure (cardiac glycosides) is not clinically relevant.
Before surgery, the physician should be told that the patient is taking enalapril because of the risk of arterial hypotension during general anesthesia.
The concomitant use of enalapril and nonsteroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (aspirin) as well as estrogen may decrease the effectiveness of enalapril and increase the risk of renal dysfunction.
The concomitant use of some diuretics (spironolactone, amiloride or triamterene) and/or additional administration of tablets containing potassium may cause increased serum potassium levels (hyperkalemia).
Drugs that cause bone marrow suppression increase the risk of neutropenia and/or agranulocytosis.
Immunosuppressants, allopurinol, cytostatics increase hematotoxicity.
Enalapril weakens the effect of agents containing theophylline.
Simultaneous use of lithium drugs may increase the side effects of lithium.
The concomitant use of Enap with cimetidine increases the half-life (T 1/2) of Enap. If a patient is already taking the above drugs or is advised to take any of them, they should tell their physician that they are taking Enap.
Special Instructions
With caution use Enap in motorists. When concomitant use with diuretics, beta-blockers the effect of Enap is increased, and with nonsteroidal anti-inflammatory drugs the effect is reduced.
Hypotension (rapid decrease in blood pressure) may be observed (even several hours after the first dose) in patients with severe heart failure or significant renal dysfunction as well as in patients with electrolyte-water balance disorders due to diuretic treatment, salt-free diet, diarrhea, vomiting or patients on hemodialysis. A marked decrease in blood pressure (BP) is usually manifested by nausea, increased heart rate (HR) and fainting.
In the case of arterial hypotension, the patient should be in a horizontal, low-headed position and a doctor should be called.
Contraindications
Side effects
Overdose
If a patient has taken too many pills in one sitting, a doctor should be called immediately.
Symptoms: excessive decrease in blood pressure (BP) up to the development of collapse, myocardial infarction, acute cerebral circulation disorder or thromboembolic complications, seizures, stupor.
Treatment: the patient is transferred to the horizontal position with a low headboard. In mild cases gastric lavage and oral administration of saline solution are indicated, in more severe cases – measures aimed at stabilization of arterial pressure (BP), IV administration of saline solution, plasma substitutes, if necessary – IV administration of angiotensin II, hemodialysis (elimination rate of enalaprilat – 62 ml/min).
Similarities
Weight | 0.015 kg |
---|---|
Shelf life | 3 years |
Conditions of storage | In a dry place, at a temperature not exceeding 25 °C |
Manufacturer | KRKA-RUS, Russia |
Medication form | pills |
Brand | KRKA-RUS |
Other forms…
Related products
Buy Enap, tablets 5 mg 20 pcs with delivery to USA, UK, Europe and over 120 other countries.